Skip to main content
. 2013 Nov 25;123(12):5269–5283. doi: 10.1172/JCI63428

Figure 7. LIF enhances the radioresistance of NPC xenografts.

Figure 7

(A) TW06_Luc2 xenografts were subjected to a single dose of 7 Gy, and tumor growth was monitored using IVIS. The tumors were intratumorally injected with PBS, LIF, or sLIFR prior to irradiation and thereafter (LIF: 150–200 ng/20 μl PBS, twice/week × 4 weeks; sLIFR: 1–2 μg/20 μl PBS, twice/week × 4 weeks). (B) Quantification of the total photon fluxes of tumors shown in A. *P < 0.05, paired t test, compared with the PBS-treated group. (C) CNE1_Luc2_GFP cells and CNE1_Luc2_sLIFR cells, which stably expressed GFP and sLIFR, respectively, were subcutaneously inoculated into legs of NOD/SCID mice and tumor responses to 7-Gy irradiation were assessed by IVIS. (D) Quantification of the total photon fluxes of tumors shown in C (*P < 0.05; **P < 0.01; paired t test). (E) Administration of rapamycin reduces LIF-mediated radioresistance. Rapamycin was given by intraperitoneal injection (3 mg/kg, once a day, 5 days/week × 3 weeks). n = 6 for each group. (F) Quantification of the total photon fluxes of tumors shown in E. *P < 0.05; **P < 0.01; paired t test.